AURAK
15.12.2018 11:51:08 CET | Business Wire | Press release
The Southern Association of Colleges and Schools Commission on Colleges (SACSCOC) officially announced the accreditation of the American University of Ras Al Khaimah (AURAK) at its 2018 Annual Meeting which was held in New Orleans, Louisiana, in the United States of America.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181215005017/en/
SACSCOC, the regional body for the accreditation of degree-granting higher education institutions in the Southern United States, has a membership of more than 800 institutions in the Southern states and other international sites approved by SACSCOC that award associate, baccalaureate, master’s, and/or doctoral degrees. SACSCOC also awards accreditation to other international institutions of higher education that satisfy all its requirements and demonstrate compliance with its accreditation standards. AURAK now joins the very small group of elite international higher education institutions that have attained SACSCOC accreditation and can enjoy the diverse benefits of membership in this highly revered organization.
“Accreditation by SACSCOC signifies that the institution has a mission appropriate to higher education, has resources, programs, and services sufficient to accomplish and sustain that mission, and maintains clearly specified educational objectives that are consistent with its mission and appropriate to the degrees its offers, and that indicate whether it is successful in achieving its stated objectives.”
“The culmination of the accreditation process is a public statement of an institution’s continuing capacity to provide effective programs and services based on agreed-upon requirements. The statement of an institution’s accreditation status with SACSCOC also represents an affirmation of an institution’s continuing commitment to the Commission’s principles and philosophy of accreditation.”
AURAK is a nonprofit, government-owned institution of higher education which provides the local, regional and international communities with a North American-style education integrated with Arabic customs and traditions. It is licensed by the Ministry of Education in the UAE and offers a total of 22 accredited undergraduate and graduate programs across a wide range of disciplines. Despite having this primary local accreditation, AURAK was determined to broaden its impact in higher education by obtaining internationally recognized institutional and program accreditations. To date, the institution has six programs accredited by the Accreditation Board for Engineering and Technology (ABET) and institutional accreditation by SACSCOC. It should be noted that in the case of institutional accreditation by SACSCOC, an institution is also expected to document and demonstrate the quality and effectiveness of all its programs and services although the agency does not award individual program accreditation.
AURAK has been working diligently towards obtaining SACSCOC accreditation since 2014 and successfully achieved candidacy status in July of 2017. This paved the way for the institution to undergo even more rigorous and comprehensive onsite review by a SACSCOC Accreditation Committee. The Committee found the institution to be in compliance with all accreditation standards and requirements. Further internal reviews were conducted by SACSCOC in keeping with its multi-tiered peer review process, the culmination of which was AURAK obtaining SACSCOC accreditation.
This was a formidable achievement that was four years in the making. It demonstrates the tenacity, determination and commitment of AURAK to achieving excellence in all its undertakings – for its students, faculty, staff and other stakeholders.
“The long- standing dream and goal has come true in a record time. The report is positive and clear.” Professor Hassan beamed proudly during the declaration of AURAK’s SACSCOC accreditation status. “Today AURAK is among the first universities in the Middle East and North Africa (MENA) region to successfully initiate and complete the entire accreditation process as an applicant institution to secure membership from the Southern Association of Colleges and Schools Commission on Colleges (SACSCOC), affirming that AURAK is not only as an institution of quality among Arabic educational institutions, but also on an international level as well. This accreditation validates our claims of providing students with a highly rigorous curriculum from the credentialed and highly knowledgeable faculty we have always strived to hire and support. AURAK has achieved in a very short time what some other institutions have failed to do in decades.
I would like to seize this opportunity to thank the AURAK family and supporters for their loyalty, dedication, and hard work. Without them, AURAK would not be the exemplar of educational excellence it is. Today our aspirations and our hard work have been realized. In gaining SACSCOC membership we join a community of highly respected institutions. We look forward to offering a vast array of educational opportunities through which we will continue to develop and excel.”
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20181215005017/en/
Contact:
American University of Ras Al Khaimah Helen Amhani , Manager, Department of Communications and Public Relations +97172210900 Ext: 1445 hamhani@aurak.ac.ae
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
